ATE322684T1 - Src sh3 bindende peptide und verfahren zu ihrer isolierung und verwendung - Google Patents
Src sh3 bindende peptide und verfahren zu ihrer isolierung und verwendungInfo
- Publication number
- ATE322684T1 ATE322684T1 AT95927423T AT95927423T ATE322684T1 AT E322684 T1 ATE322684 T1 AT E322684T1 AT 95927423 T AT95927423 T AT 95927423T AT 95927423 T AT95927423 T AT 95927423T AT E322684 T1 ATE322684 T1 AT E322684T1
- Authority
- AT
- Austria
- Prior art keywords
- peptides
- amino acid
- acid residues
- src
- binding affinities
- Prior art date
Links
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
- G01N33/5011—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing antineoplastic activity
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/001—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof by chemical synthesis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/04—Linear peptides containing only normal peptide links
- C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/04—Linear peptides containing only normal peptide links
- C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
- G01N33/502—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects
- G01N33/5041—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects involving analysis of members of signalling pathways
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/573—Immunoassay; Biospecific binding assay; Materials therefor for enzymes or isoenzymes
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Molecular Biology (AREA)
- Biomedical Technology (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Hematology (AREA)
- Urology & Nephrology (AREA)
- Biochemistry (AREA)
- Organic Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biotechnology (AREA)
- Microbiology (AREA)
- Food Science & Technology (AREA)
- Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- Cell Biology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Toxicology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Public Health (AREA)
- Gastroenterology & Hepatology (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Veterinary Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Zoology (AREA)
- Epidemiology (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US08/278,865 US6303574B1 (en) | 1994-07-22 | 1994-07-22 | Scr SH3 binding peptides and methods of isolating and using same |
US48355595A | 1995-06-07 | 1995-06-07 |
Publications (1)
Publication Number | Publication Date |
---|---|
ATE322684T1 true ATE322684T1 (de) | 2006-04-15 |
Family
ID=26959309
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
AT95927423T ATE322684T1 (de) | 1994-07-22 | 1995-07-24 | Src sh3 bindende peptide und verfahren zu ihrer isolierung und verwendung |
Country Status (7)
Country | Link |
---|---|
EP (1) | EP0772773B1 (de) |
JP (2) | JP4215274B2 (de) |
AT (1) | ATE322684T1 (de) |
AU (1) | AU3146095A (de) |
CA (1) | CA2195629A1 (de) |
DE (1) | DE69534920T2 (de) |
WO (1) | WO1996003649A1 (de) |
Families Citing this family (15)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA2184631A1 (en) * | 1994-03-17 | 1995-09-21 | John C. Cambier | Product and process for regulating signal transduction pathways |
US6184205B1 (en) * | 1994-07-22 | 2001-02-06 | University Of North Carolina At Chapel Hill | GRB2 SH3 binding peptides and methods of isolating and using same |
JPH11509172A (ja) * | 1995-04-07 | 1999-08-17 | サイトジェン・コーポレーション | 目的の機能ドメインを有するポリペプチドおよびそれの同定および利用法 |
EP0971726A4 (de) * | 1996-10-21 | 2002-07-24 | Mark E Howard | Peptide zur hemmung von retroviren |
WO1998045704A2 (en) | 1997-04-07 | 1998-10-15 | Bioimage A/S | A method for extracting quantitative information relating to an influence on a cellular response |
IT1291110B1 (it) * | 1997-04-15 | 1998-12-29 | Istituto Europ Di Oncologia S | Interattori intracellulari e specificita' di legame del dominio eh |
GB9711148D0 (en) * | 1997-05-31 | 1997-07-23 | Peptide Therapeutics Ltd | Human MAFA |
JP2002527761A (ja) * | 1998-10-15 | 2002-08-27 | バイオイメージ エイ/エス | 細胞応答への影響に関する量的情報を入手するための改良方法 |
US6794144B1 (en) | 1999-05-26 | 2004-09-21 | Licentia Ltd. | Methods and materials for generating SH3 domains with tailored binding properties |
EP2752196A1 (de) * | 2013-01-03 | 2014-07-09 | Université Bordeaux Segalen | Selektive NOX-1-Hemmerpeptide und Verwendungen davon |
WO2015097077A2 (en) | 2013-12-27 | 2015-07-02 | F. Hoffmann-La Roche Ag | Systemic discovery, maturation and extension of peptide binders to proteins |
JP2018513166A (ja) | 2015-04-20 | 2018-05-24 | エフ.ホフマン−ラ ロシュ アーゲーF. Hoffmann−La Roche Aktiengesellschaft | 系統的な探索、成熟化および伸長プロセスにより同定した、タンパク質に対する特異的ペプチドバインダー |
CN106589062B (zh) * | 2016-12-09 | 2020-03-24 | 上海市第一妇婴保健院 | 靶向Grb2蛋白的抗肿瘤共价多肽抑制剂及其制备方法和应用 |
WO2019136109A1 (en) | 2018-01-02 | 2019-07-11 | Ampliphi Biosciences Corporation | Therapeutics bacteriophage compositions for treating staphylococcus infection |
EP3757217A1 (de) * | 2019-06-27 | 2020-12-30 | GlaxoSmithKline Biologicals S.A. | Verfahren zur proteinaufreinigung |
Family Cites Families (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU2159895A (en) * | 1994-03-11 | 1995-09-25 | Ariad Pharmaceuticals, Inc. | Methods and materials for identifying inhibitors of molecular interactions mediated by sh3 domains |
-
1995
- 1995-07-24 EP EP95927423A patent/EP0772773B1/de not_active Expired - Lifetime
- 1995-07-24 WO PCT/US1995/009382 patent/WO1996003649A1/en active IP Right Grant
- 1995-07-24 DE DE69534920T patent/DE69534920T2/de not_active Expired - Fee Related
- 1995-07-24 JP JP50593696A patent/JP4215274B2/ja not_active Expired - Fee Related
- 1995-07-24 AU AU31460/95A patent/AU3146095A/en not_active Abandoned
- 1995-07-24 AT AT95927423T patent/ATE322684T1/de not_active IP Right Cessation
- 1995-07-24 CA CA002195629A patent/CA2195629A1/en not_active Abandoned
-
2007
- 2007-04-16 JP JP2007107630A patent/JP2007259856A/ja active Pending
Also Published As
Publication number | Publication date |
---|---|
JPH10503369A (ja) | 1998-03-31 |
EP0772773A4 (de) | 1999-08-11 |
AU3146095A (en) | 1996-02-22 |
DE69534920T2 (de) | 2007-04-05 |
CA2195629A1 (en) | 1996-02-08 |
JP2007259856A (ja) | 2007-10-11 |
JP4215274B2 (ja) | 2009-01-28 |
EP0772773B1 (de) | 2006-04-05 |
WO1996003649A1 (en) | 1996-02-08 |
EP0772773A1 (de) | 1997-05-14 |
DE69534920D1 (de) | 2006-05-18 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP1538157A3 (de) | Sh3-bindender Peptide und deren Verwendung | |
ATE322684T1 (de) | Src sh3 bindende peptide und verfahren zu ihrer isolierung und verwendung | |
Krumpe et al. | T7 lytic phage‐displayed peptide libraries exhibit less sequence bias than M13 filamentous phage‐displayed peptide libraries | |
Sparks et al. | Identification and characterization of Src SH3 ligands from phage-displayed random peptide libraries. | |
Linn et al. | Using molecular repertoires to identify high-affinity peptide ligands of the WW domain of human and mouse YAP | |
IL131435A0 (en) | In vitro peptide or protein expression library | |
WO2000068263A3 (en) | Stereoselective antifibrillogenic peptides and peptidomimetics thereof | |
HU9201687D0 (en) | Preparation of sets from peptid mixtures with polycomponents and their use for the identification of biologically active peptides | |
EP2267019A3 (de) | Polypeptide zur Bindung an das B-Lymphozyten-stimulatorische Protein (BLyS) | |
CA2302147A1 (en) | Methods for protein screening | |
GB9722320D0 (en) | Human cell cycle checkpoint proteins | |
EP0871661A4 (de) | Neue proteindomäne, welche tyrosin-pharphoryliarte proteine bindet | |
WO1997012039A3 (en) | Sh2-containing inositol-phosphatase | |
WO2004069200A3 (en) | Specific inhibitors of nfat activation by calcineurin and their use in treating immune-related diseases | |
WO1996013592A3 (en) | Protein kinase npk-110 | |
WO1996035715A3 (en) | Pcna binding substance | |
WO2002026783A3 (en) | Chimeric retroviral gag genes and screening assays | |
GB9816514D0 (en) | Novel method | |
DE69504795D1 (de) | Methoden zur synthese und reinigung von peptiden | |
DK0667781T3 (da) | Peptidbaserede diagnostiske og terapeutiske midler til spondylarthropatier | |
Harfst et al. | A comparative analysis of the phosphorylation and biochemical properties of wild type and host range variant DNA binding proteins of human adenovirus 5 | |
Coulon et al. | Cyclic peptides selected by phage display mimic the natural epitope recognized by a monoclonal anti‐colicin A antibody | |
EP0331184A3 (de) | Peptid-Gegenwerte von Nichtpeptiden und Verfahren zum Entwurf dafür | |
WO2004005318A3 (en) | Peptides comprising aromatic d-amino acids and methods of use | |
WO2001027269A3 (en) | Vip54 protein and related materials |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
RER | Ceased as to paragraph 5 lit. 3 law introducing patent treaties |